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Background: Pyridinium cross-links pyridinoline (PYD) and deoxypyridinoline (DPD) are established
markers of collagen degradation. Measurement of PYD and DPD can be used to evaluate changes in bone
turnover in patients with metabolic bone disease and to monitor response to anti-resorptive treatment.
Objective: To develop a method to extract and measure urine free PYD (fPYD) and free DPD (fDPD) by
liquid chromatography tandem mass spectrometry (LC–MS/MS). The method was used to quantify urine
samples from 172 healthy individuals and 63 patients diagnosed with metabolic bone disease.
Method: Acidified urine samples were extracted using solid phase extraction with cellulose slurry. PYD
and DPD were separated by reversed-phase, ion-paired chromatography prior to MS/MS detection.
Results: The fully validated method showed good agreement with other laboratories in the UK National
External Proficiency Scheme (UK NEQAS). The method was compared against two commercial
immunoassays for fDPD and pyridinium cross-links, r2 were 0.906 and 0.816 respectively. Urine concen-
trations of fDPD/Cr and fPYD/Cr were significantly higher in the patients than healthy individuals
(p < 0.001). An average (±SD) fDPD:fPYD ratio of 0.29 (±0.08) was consistently observed across all
subgroups. A markedly increased fDPD:fPYD ratio of 8.9 was observed in a patient with type VI
Ehlers–Danlos Syndrome (EDS).
Conclusion: Simultaneous measurement of two free pyridinium cross-links provides a valuable, cost
effective assessment tool for use in the diagnostic work-up of patients with metabolic bone disease.
Improvements in sample extraction efficiency have increased assay specificity and analysis throughput.
The use of the fDPD:fPYD ratio can assist in the diagnosis of type VI EDS.
 2016 The Association for Mass Spectrometry: Applications to the Clinical Lab (MSACL). Published by
Elsevier B.V. This is an open access article under the CCBY license (http://creativecommons.org/licenses/by/
4.0/).1. Introduction
The extracellular matrix in bone consists of 90% type I collagen.
The mechanical structure is stabilised by the formation of mature,
trivalent cross-links that bond adjacent collagen chains covalently
in a triple-helical protein structure. These cross-links are amino
acid derivatives of hydroxypyridinium and can be divided into
two main groups: pyridinoline (PYD) and deoxypyridinoline
(DPD). PYD is present in several connective tissues, whereas DPD
is mainly found in bone and mineralised tissue. Bone is constantly
remodelled, the coupled process of osteoclastic resorption and
osteoblastic formation release many specific biochemical com-
pounds of bone turnover into serum and urine. During the processof bone resorption, the cross-links are released into circulation as
free or bound to peptides or sugars, prior to excretion in urine.
The amount of pyridinium cross-links in urine reflects the extent
of type 1 collagen degradation of the whole body.
Measurement of pyridinium cross-links can be useful in the
identification of diseases characterised by increased bone resorp-
tion [1]. Assessment of bone turnover status enables the clinician
to monitor patient response to anti-resorptive therapy for several
metabolic bone diseases [2,3]. Immunoassays and high perfor-
mance liquid chromatography (HPLC) methods that quantify free,
bound and total (free plus bound) forms of PYD and DPD have been
described [4–6]. Assays are described where total pyridinium
cross-links are extracted by acid hydrolysis with concentrated
hydrochloric acid added to urine in a pressurised container and
heated at temperature between 110 and 180 C for up to 24 h
[7–9]. Modern chromatographic techniques coupled with
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sitivity that allows measurement of the free fraction in urine with-
out acid hydrolysis. An extraction procedure is necessary to
remove interfering fluorophores present in the urine matrix before
HPLC separation and detection.
Commercial enzyme immunoassays (EIA) are available on auto-
mated platforms (Immulite Pyrilinks-D, Siemens, USA) and 96-
well microtitre plate format (Quidel MicroVue, San Diego, CA,
USA). The automated Pyrilinks-D assay for measurement of DPD
in urine claims 100% specificity for DPD with 3% cross reactivity
with PYD [16], whereas the MicroVue DPD assay claims high affin-
ity for free DPD, with negligible binding to PYD and peptide bound
DPD/PYD [17]. The MicroVue pyridinium cross-links assay employs
an antibody raised with cross reactivity for both PYD and DPD [18].
In order to obtain final PYD concentration, results must also be
assayed for DPD and this subtracted from the total pyridinium
cross-links.
Liquid chromatography tandem mass spectrometry (LC–MS/
MS) is increasingly becoming the method of choice for quantitative
measurement of small molecules. Recent advancements in LC–MS/
MS instrumentation have improved the limits of sensitivity and
selectivity by orders of magnitude that classical chromatography
or immunoassays cannot achieve. Kindt et al. [19] first reported a
LC–MS/MS assay for total PYD and DPD in urine and tissue hydro-
lysates, where samples were acid hydrolysed (6 N HCL overnight at
116 C) to release peptide-bound PYD/DPD. The debate remains
whether the determination of total or free PYD and DPD can pro-
vide more information on collagen metabolism in patients. The
correlation between free and total collagen cross-links varies by
small degrees in chronic joint diseases [5]. In this paper, we
describe the use of urinary free DPD (fDPD) and free PYD (fPYD)
measurements as markers of bone degradation.2. Materials and methods
2.1. Urine sample collection
Method comparisons were carried out on residual urine sam-
ples previously collected in the course of routine care. Samples
were anonymised to the researchers at point of access, in accor-
dance with generic ethical approval [20]. Random second morning
void fasting urines were collected into sterile containers stored at
20 C and protected from light prior to analysis. Written
informed consent was obtained from all study participants, in
accordance with the rules of the local ethics committee. Urine sam-
ples from healthy individuals (n = 172) and patients who presented
with metabolic bone disease (n = 63) were analysed by the LC/MS–
MS method.
2.2. Chemicals and reagents
Highly purified PYD/DPD calibration solution and acetylated
PYD (INT-PYD) were purchased from Quidel Corporation (San
Diego, CA, USA). LCMS grade water and methanol, and analytical
grade tetrahydrofuran (THF), heptafluoro-butyric acid (HFBA),
butan-1-ol and hydrochloric acid were obtained from Fisher Scien-
tific (Loughborough, UK). Glacial acetic acid was purchased from
VWR (Lutterworth, UK). Cellulose microcrystalline was supplied
by Alfa Aesar (Heysham, UK).
2.3. Calibration standards and quality control material
Human urine pyridinium cross-links calibrator was purchased
from Immundiagnostik (Bensheim, Germany). Two urine pools
were donated by laboratory staff with permission to be used asinternal quality control (IQC) materials. High and low values were
obtained and assigned to each pool using the mean value of 20
inter batch replicate analyses. The urine pools were transferred
into 1.5 mL microcentrifuge vials and kept frozen in the dark at
20 C. Aliquots from both pools were assayed in each analytical
batch.
2.4. Solid phase extraction procedure for fPYD and fDPD in urine
Calibration standard, IQC material or urine samples (0.5 mL)
were spiked with 1 mL of freshly prepared acetylated PYD (INT-
PYD) in 10 mL glass tubes. Hydrochloric acid (0.5 mL) was added
to all tubes, followed by 4 mL of butan-1-ol and 1 mL of cellulose
slurry suspended in butan-1-ol/water/glacial acetic acid (4:1:1, v/
v) solution. The tubes were capped, mixed by vortex for 30 s fol-
lowed by 20 end over-end inversion before being left to stand for
30 min at room temperature in a fume hood.
Solid phase extraction procedure was carried out on a PRES-
SURE+48 positive pressure manifold (Biotage, Uppsala, Sweden)
using nitrogen gas supplied from a nitrogen generator (Peak,
Scotland, UK) at flow rate of 30 L/min. Acidified urines were trans-
ferred into respective empty ISOLUTE column reservoir (Biotage,
Uppsala, Sweden) placed on the positive pressure manifold with
20 lm polyethylene frits pushed to the bottom of each column.
Once the urine mixture was allowed to pass through the column,
the columns were washed with 6 mL of butanolic solution followed
by 0.5 mL THF. During each stage the wash solutions were drained
to waste. After each wash step the columns were dried using
nitrogen gas pumped at 6 bar of pressure to remove residual wash
solutions. Pyridinium cross-links were eluted off into microcen-
trifuge vials using 0.5 mL of 0.2% HFBA. The eluents collected were
centrifuged at 10,000g for 5 min prior to injection into the LC–
MS/MS. Using our 48-position positive pressure manifold, a batch
of 48 samples can be processed in 2 h.
2.5. Liquid chromatography
Urine extracts were injected into a Rheos Allegro UPLC pump
(Flux Instruments, Switzerland) controlled by Janeiro II software.
A Waters 2777 Sample manager (Waters Corp., Milford, MA,
USA) equipped with 3-drawer cooler stack regulated at 10 C was
used for sample injection. Chromatographic separation was
achieved using the Accucore (Thermo Scientific, Finland) C18
50  2.1 mm, 2.6 lm, reversed-phase solid core particle column
heated at 55 C and protected by a 2 lm, 6.35 mm  24 mm guard
cartridge. A gradient elution profile was set up with column flow
rate at 0.4 mL/min. At the start of the gradient the mobile phase
consisted of 85%:15% (A) LCMS grade water in 0.1% HFBA and (B)
LCMS grade methanol in 0.1% HFBA. The gradient was gradually
increased to 99% (B) then returned back to starting gradient in
4.5 min. Solvent divert was employed to divert the ion suppression
region of the separation to waste in order to minimise contamina-
tion to the source of the mass spectrometer.
2.6. Tandem mass spectrometry analysis
LC–MS/MS analysis of PYD, DPD and INT-PYD was performed
using Micromass Quattro Ultima Pt mass spectrometer (Waters
Corp., Milford, MA, USA) with an integrated electrospray ionisation
(ESI) source operated in positive mode. Capillary voltage was kept
at 3.0 kV and RF lens 1 and 2 were set at 0.1. Source temperature
was maintained at 130 C. Nitrogen was used as both nebuliser
gas at flow rate of 30 L/h and as desolvation gas at flow rate of
850 L/h at 350 C. Sample cone voltage was 35 kV, collision
energies for PYD, DPD and INT-PYD were 40 kV. Argon was used
as collision gas. Sample analysis was performed in multiple reaction
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each of the compounds were identified by direct infusion of
extracted standards into the ion source via a T-connector. The pre-
cursor to product ion transition for PYD, DPD and INT-PYD were
429 > 82, 413 > 84 and 471 > 128, respectively. MassLynx version
4.1 and QuanLynx software (Waters Corp., Milford, MA, USA) were
used for system control, data acquisition, baseline integration and
peak quantification.
2.7. Method validation
Method validation was performed following guidance from the
2013 U.S. Food and Drug Adminstration (FDA) [21] and the 2012
European Medicines Agency (EMA) [22]. The calibration standards
were matrix matched to human urine. Quantification of fPYD and
fDPD in unknown samples was performed in batches of up to 48
samples, each batch included a set of standards and IQC samples
assayed at set points throughout the batch. The concentration of
the IQCs ranged from the lowest level (within three times the
lower limit of quantification), to the top end of the analytical limit.
The IQCs provided the basis of accepting or rejecting the batch, IQC
results must be within ±2SD from the mean value. An assay is
rejected when IQC failed to fulfil Westgard acceptance criteria [23].
2.8. Linearity
Linearity of the method was evaluated by analysing stock stan-
dards prepared using Quidel PYD/DPD calibration solutions. PYD
concentrations ranged from 0 to 2000 nmol/L and DPD up to
1000 nmol/L were prepared and analysed. The Calibration curve
was constructed by plotting the ratio of analyte peak area to INT-
PYD peak area against the concentration of their respective stan-
dards. Calibration curveswere accepted as linear if theweighted lin-
ear regressionproduced a correlation coefficient (r2) value of >0.990.
2.9. Imprecision
Intra and inter-assay imprecision of the method were assessed
by running IQC materials twenty times within a single run and sep-
arately over a three month period (n = 54). Variation was expressed
in terms of standard deviation (SD) and coefficient of variation per-
centage (%CV). The acceptance criteria defined that %CV should not
exceed 10% intra-assay and 15% inter-assay across the working
range of the assay [21].
2.10. Ion suppression
Ion suppression experiment was performed by post column
infusion of an 10 lmol/L aqueous mixture of PYD and DPD solution
via a T-junction at a flow rate of 20 lL/min, while samples of
extracted phosphate buffered saline (PBS) blank and human urine
were injected simultaneously via the liquid chromatography sys-
tem at 0.4 mL/min.
2.11. Recovery efficiency
Urine samples (n = 10) were aliquoted and spiked with two dif-
ferent concentrations of PYD at 110 nmol/L and 550 nmol/L, and
DPD at 45 nmol/L and 250 nmol/L. Assay recovery was determined
by calculating the percentage of the measured value against the
sum of endogenous value plus spiking concentration.
2.12. Lower limit of quantification and detection
Lower limit of quantification (LLOQ) was determined by the
lowest concentration quantifiable for which intra-assay precisionCV of 20% over 12 replicates and minimum peak signal-to-noise
ratio of 10:1 [21]. Lower limit of detection (LLoD) was determined
by the lowest concentration that produced a minimum peak area
of five times the response produced by the blank [21,22].
2.13. Method comparison
Method comparisons were carried out against two commer-
cially available immunoassays. PYD values obtained from LC–MS/
MS were compared against MicroVue pyridinium cross-links
enzyme immunoassay (Quidel, San Diego, CA, USA), in 96-well
microtitre plate format performed manually using Wellwash
automatic plate washer and Multiskan GO spectrophotometer
(Thermo Scientific, Finland). DPD comparison was carried out
against Pyrilinks-D solid phase chemiluminescent enzyme-
labelled immunoassay analysed on the Immulite 1000 automated
immunoassay system (Siemens, USA).
2.14. Urine creatinine measurements
Urine creatinine was measured to obtain fPYD and fDPD to
urine creatinine ratio. Samples were analysed using Roche 2nd
generation kinetic colorimetric assay based on the Jaffé method
performed on the COBAS C501 analyser (Roche, Burgess Hill,
UK). The inter-assay CV ranged from 1.3% to 2.1% and intra-assay
ranged between 1.6% and 4% across the assay working range. Exter-
nal quality control (UK NEQAS) return showed an inter-laboratory
CV of 2.2%.
fPYD and fDPD results obtained from LC–MS/MS analysis were
normalised for variations in renal function and concentrated urine
by dividing the cross-links value in nmol/L by creatinine value in
mmol/L. The final results were expressed as nmol/L per mmol/L
creatinine.
2.15. Statistical data analysis
Linear regression analysis and Bland–Altman plots were con-
structed and analysed by Statistical Package for the Social Science
(SPSS) version 22.0.0.1 (IBM, New York, USA). One-way ANOVA
was used to compare variables in healthy and patient groups.
Significance was defined as p < 0.05.3. Results
PYD, DPD and internal standard peaks were eluted at 1.68, 1.78
and 1.91 min respectively (Fig. 1). The solid core particle column
produced clean distinct peaks, minimal baseline noise was
observed around the peaks of interest. Ion suppression studies
showed the region of interference occurred during the early part
of the separation (Fig. 2), solvent divert was subsequently
employed to divert the ion suppression region to waste. At the
end of each gradient cycle a 100% methanol column wash step
was incorporated to remove residual waste. Total run time from
injection-to-injection was 4.5 min.
Standard curves of PYD and DPD (Fig. 3) were generated by
plotting the analyte:INT-PYD peak area ratio against the concentra-
tion of standards ranging from 0 to 2000 nmol/L for PYD and 0 to
1000 nmol/L for DPD. Linear regression analysis consistently pro-
duced r2 > 0.998. The LLoD and LLoQ for PYD were 5 nmol/L and
6 nmol/L, respectively. DPD were 2 nmol/L and 2.5 nmol/L respec-
tively. The CV of PYD at 6nmol/L was 14.3% and DPD at 2.5 nmol/L
was 15.9%.
Imprecision of the method was assessed by analysing two urine
pools to establish the intra- and inter-assay variations. Intra-assay
imprecision was determined by analysing twenty consecutive
Fig. 2. Ion suppression from direct infusion. Reduction in baseline signal was observed in (A) during co-injection of extracted urine sample and post column infusion of PYD
and DPD. Ion suppression occurred during 1.1–1.4 min, prior to the elution of (B) PYD, and (C) DPD peaks generated from an extracted urine sample without compound
infusion.
Fig. 1. Typical urine sample chromatograms of PYD, DPD and acetylated PYD internal standard following a 30 lL injection. Urine concentrations: fPYD 254.3 nmol/L and fDPD
50.5 nmol/L.
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±SD) for PYD were 9.1% (75.7 ± 6.9 nmol/L) and 3.8% (739.1 ±
27.9 nmol/L) respectively, DPD were 9.9% (17.9 ± 1.8 nmol/L) and
9.9% (150.7 ± 6.9 nmol/L) respectively. Inter-assay imprecision was
determined by analysing the same lot of low and high urine pools
over 54 batches during a three-month evaluation period. The CVs
(mean concentration, ±SD) for PYD were 10.3% (69.4 ± 7.1 nmol/L)and 10% (747.5 ± 74.7 nmol/L) respectively, DPD were 10%
(16.5 ± 1.6 nmol/L) and 13.1% (143.4 ± 18.7 nmol/L).
Extraction recoverywas evaluated by determining the amount of
cross-links recovered from the amount spiked prior to extraction.
With the use of an internal standard, mean recovery for PYD was
106.5% (range 96.4–116.5%) and for DPD was 104.2% (range 102.0–
106.3%) (Table 1). The data indicated that the SPE procedure was
Fig. 3. Typical standard curves of (a) PYD, and (b) DPD constructed by plotting the response of each standard on the y-axis against their respective concentrations (nmol/L) on
the x-axis. Analytes response were determined by the ratio of the peak area of the standards to the peak area of the internal standard. Regression analysis showed a typical
correlation coefficient r2 > 0.99.
Table 1
Recovery efficiency was determined by adding known quantities of (a) PYD and (b) DPD to 10 aliquots of the same urine samples containing endogenous levels of collagen
crosslinks. Each aliquot was individually spiked and assayed over separate runs.
Endogenous fPYD (nmol/L) Spiked (nmol/L) Mean (±SD) measured value (nmol/L) Recovered mean (±SD) % recovery mean (±SD)
1(a)
151 110 257.1 (±7.3) 106.1 (±7.3) 96.4 (±6.6)
151 550 791.8 (±11.6) 640.8 (±11.6) 116.5 (±2.1)
1(b)
28 45 73.9 (±4.4) 45.9 (±4.4) 102.0 (±9.9)
28 250 293.7 (±8.9) 265.7 (±8.9) 106.3 (±3.5)
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themethodwas able to determine the amount recovered accurately.
An increase in assay CV toP20%was observed in spiked urine sam-
ples extracted without internal standard.
Method comparisons between LC–MS/MS and immunoassays
are illustrated by Passing–Bablok regression and Bland–Altman
plots (Fig. 4). The line of best fit generated a slope of 0.8369
(r2 = 0.8162) for PYD, DPD produced a slope of 1.1071 and
(r2 = 0.9057). Bland–Altman plot demonstrated a negative bias of
7.94% (r = 0.903, p < 0.001) for the PYD values generated by LC–
MS/MS method, whereas a small positive bias of 3% (r = 0.952,
p < 0.001) was observed in DPD results between the methods.
Materials from external quality controls (UK NEQAS) (n = 20)
were analysed blind using our LC–MS/MS method. Reports from
distributions during 2014–2015 on urine free DPD showed bias
ranged between 14.5 and +4.5% compared to all laboratory
trimmed mean (ALTM). There were only six participants in the
scheme and we were the only LC–MS/MS participant. Our assay
showed good agreement (r2 = 0.9464) with all laboratory trimmed
mean (Fig. 5).
fDPD and fPYD were measured in healthy individuals (n = 172)
using the LC–MS/MS method, the results were normalised per
mmol of urine creatinine. The patient groups (n = 63) were divided
by the clinical diagnoses into Paget’s disease of bone, osteoporosis,
and a subgroup of patients with disorders associated with abnor-
mal bone turnover including osteogenesis imperfecta, osteomala-
cia, bone fracture and primary hyperparathyroidism. The
concentrations of both cross-links were significantly increased inall patient groups (Fig. 6a and b). Despite a substantial increase
in cross-links, fDPD:fPYD ratio observed in patient groups did not
show a significant difference (p > 0.27) from the healthy group
(Fig. 6c). During routine healthcare service, we have identified a
patient with fDPD/Cr of 722.7 nmol/mmol, fPYD/Cr of 80.8 nmol/
mmol with a fDPD:fPYD ratio of 8.9. Review of clinical records
showed the patient presented with hypermobility particularly of
the joints of the fingers, wrists, ankles, kyphoscoliosis and skin
hyperextensibility. The increase in cross-links indicated high bone
resorption and collagen degradation. The elevated fDPD:fPYD ratio
indicated an abnormal urinary excretion pattern that was consis-
tent with the diagnosis of type VI of Ehlers–Danlos Syndrome
(EDS Type VI). Subsequent genetic analysis proved the presence
of a homozygous missense mutation of the procollagen-lysine, 2-
oxoglutarate 5-dioxygenase 1 (PLOD1) gene in exon 13 resulting
in decreased activity of lysyl hydroxylase enzyme.
4. Discussion
We have developed a robust LC–MS/MS assay for urine fPYD
and fDYD. The assay was validated against published acceptance
criteria for clinical and research use. In laboratories where there
is often a high demand on workload, a multiplex liquid chromatog-
raphy system can be utilised to perform large batches of samples
during the night, allowing technician time to be freed to perform
other tasks during the day. LCMS assays using single quadrupole
[24] and tandem quadrupole LC–MS/MS [19] instruments
have been published. Our method described the use of a triple
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Fig. 4. Method of comparison of the LC–MS/MS method with (a) Quidel MicroVue pyridinium cross-links enzyme immunoassay method (n = 39), and (b) Siemens Immulite
Pyrilinks-D DPD enzyme immunoassay (n = 70). Solid line in the graph represents the fitted regression line; dotted line is the line of identity. Bland–Altman plots comparing
the mean concentrations of PYD and DPD against the percentage difference between LC–MS/MS and Immunoassay methods. LC–MS/MS assay showed an average negative
bias of 7.94 nmol/L (r = 0.903, p < 0.0001) for PYD (n = 39), and an average positive bias of 3.0 nmol/L (r = 0.952, p < 0.0001) for DPD (n = 70). The dashed lines representing
the 95% limits of agreement are shown.
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Fig. 5. Comparison of urine fDPD returns (n = 20) with UK NEQAS all laboratory
trimmed mean (ALTM). Solid line in the graph represents the fitted regression line;
dotted line is the line of identity.
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spray (ESI) source coupled with two radio frequency only ion tun-
nels. This multi stage process removes unwanted adducts and neu-
tral ions, thus enhances fragmentation efficiency of sample ions
and maximises sensitivity. Compound identification based on m/z
detection of precursor to product ion transition is highly specific.The selectivity ensures the assay is not interfered with by other
compounds with similar properties of which may co-elute
chromatographically. Our method has demonstrated the ability
to analyse multiple compounds simultaneously with performance
characteristics that satisfy industry standard criteria for method
validation. The use of solid core columns has improved peak
resolution, signal-to-noise ratio, and increased speed of chromato-
graphic separation. Non porous columns have higher plate count
than conventional porous columns due to the high packing density.
Our run time of 4.5 min is one of the shortest compared to other
documented HPLC methods [4,11,13,24].
Acetylated PYD as an internal standard is commonly used in
HPLC methods. Reports of cross talk with PYD possibly due to
impure stock material, or due to the removal of an acetyl group
during the acid hydrolysis step and/or by MS/MS collision have
been documented [19]. We did not encounter such cross-
transitional interferences; injections of extracted blank material
spiked with acetylated PYD confirmed the absence of PYD and
DPD peaks. Inclusion of internal standard is essential to ensure loss
of analyte during the analytical process is compensated.
Black et al. [9] first described the use of ion pairing agent to
tackle issues with poor column retention due to the hydrophilic
nature of PYD and DPD. Heptafluorobutyric acid (HFBA) is a com-
monly used ion-pairing agent in HPLC assays [4,11,13,24]. How-
ever, in LC–MS/MS, the low volatility of HFBA posed a potential
problem with source contamination that could result in loss of
sensitivity. We kept the amount of HFBA in the mobile phases to
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Fig. 6. Box and whisker plots showing the concentrations of (a) fPYD, (b) fDPD, and
(c) fDPD:fPYD in healthy individuals (n = 172) and patients (n = 63) diagnosed with
Paget’s disease of bone, osteoporosis and other metabolic bone disorders. Urinary
concentrations of fPYD and fDPD are expressed as molar ratios with creatinine
concentration (nmol/mmol). One way ANOVA analysis showed significant increase
in patient groups when compared to healthy subjects. Paget’s disease of bone
(fPYD/Cr: p < 0.0001, fDPD/Cr: p < 0.0001); osteoporosis (fPYD/Cr: p < 0.0001, fDPD/
Cr: p < 0.0001); and other bone disorders (fPYD/Cr: p < 0.0001, fDPD/Cr: p < 0.0001).
fDPD:fPYD ratio showed no significant difference in patient groups when compared
to healthy individuals [Paget’s disease of bone (p = 0.35), osteoporosis (p = 0.28),
other bone disorders (p = 0.27)]. Results are expressed as mean (r), median,
interquartile range and 95% population interval.
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reduce fouling of the ion source.
Our LC–MS/MS assay was evaluated against two established
commercial immunoassays for PYD and DPD and both showed
good overall correlation. A negative bias was observed for PYD val-
ues generated by LCMS/MS in comparison to MicroVue immunoas-
say, which is greater at higher concentrations. This finding is
expected as the anti-pyridinium cross-links antibody in the Micro-
Vue immunoassay cross reacts with both PYD and DPD [18],
whereas the LC–MS/MS method is able to detect one cross-link
with zero cross talk. Although LC–MS/MS results correlated with
immunoassays in a concentration-dependent manner, the variabil-
ity of the values observed in the Bland–Altman plots (Fig. 4c and d)
is likely to be due to the difference in analyte recovery in urine
samples. The use of internal standard in a multiplexed LC–MS/
MS method allows for the correction of under/over recovery in
each individual sample, such an approach in not possible in single-
plex immunoassays.
Using our LC–MS/MS method, we have measured and compared
the concentrations of cross-links in a healthy population and in
patients with diseases affecting bone turnover. In agreement with
previous publications, our findings showed increased levels of fPYD
and fDPD in the patient groups [1,12,14,25–28]. Paget’s disease of
bone and osteoporosis are diseases known to have increased osteo-
clast activity, elevated urine fPYD and fDPD excretion were
observed in untreated patients [12]. In patients with vertebral frac-
tures [29], primary hyperparathyroidism [12], cancer related bone
disease [30–32] and thyrotoxicosis [33,34] there may also be ele-
vated pyridinium cross links up to 2–3 times the upper limit of
normal. Baseline measurement of fPYD and fDPD is a valuable tool
in the evaluation of bone turnover status in patients and can be a
guide to type and severity of disease [12,35–40]. A decrease in
value post treatment can be observed following bisphosphonate
therapy long before a significant change in bone mineral density
can be established [32,34].
The clinical utility of fDPD:fPYD ratio as a diagnostic tool for
EDS Type VI is an advantageous aspect of the LC–MS/MS assay. This
autosomal recessive disorder can be caused by single nucleotide
polymorphism in procollagen-lysine, 2-oxoglutarate 5-
dioxygenase 1 (PLOD1). Deficiency in the synthesis of resultant
enzyme lysyl hydroxylase leads to under-hydroxylation of collagen
lysyl residues. Abnormal DPD and PYD formation and excretion
pattern results in a marked increase in DPD:PYD ratio as observed
in the patient whose sample was referred to our laboratory for
analysis. The abnormal ratio is a characteristic feature of patients
presenting with EDS Type VI that requires measurement of both
cross-links [39,41,42]. Simultaneous measurement by LC–MS/MS
is more cost effective compared to immunoassays, where samples
have to be assayed twice to obtain the required measurements.
In summary, we have developed and validated a method to
measure urine fPYD and fDPD using an LC–MS/MS instrument that
is widely available in clinical and research laboratories. Based on
previously published methodologies, we have made improvements
in both sample extraction and detection techniques to increase
assay quality and efficiency. The availability of this assay provides
a valuable, cost effective diagnostic tool for patients with diseases
affecting bone turnover and disorders of collagen metabolism.Author contributorship
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